Masimo Corporation - MASI STOCK NEWS

Masimo (NASDAQ: MASI) and Qualcomm Technologies have partnered to develop a next-generation smartwatch reference platform for OEMs building Wear OS by Google smartwatches. This collaboration combines Masimo's clinically proven biosensing technologies with Qualcomm's Snapdragon wearable platforms to enhance the wearable ecosystem. The platform will feature:

• Masimo's health and wellness tracking tools
• High-performance, ultra-low power SoCs
• Advanced wireless and cellular communications

OEMs will benefit from production-ready designs, incorporating Masimo's biosensing technology and Qualcomm's Snapdragon platforms, enabling rapid market entry at scale. The platform will include Masimo's Signal Extraction Technology (SET) and offer the same capabilities as Masimo W1 and upcoming Masimo Freedom wearables.

Masimo (NASDAQ: MASI) has announced a partnership with Google to develop a reference platform for Wear OS smartwatches. This collaboration aims to help original equipment manufacturers (OEMs) efficiently build and launch high-performing smartwatches. The platform will incorporate Masimo's advanced biosensing technologies, leveraging their expertise in hospital monitoring solutions.

Key features of the reference platform include:

• Trusted health and wellness tracking tools
• Seamless integration with Android smartphones
• High-quality, high-performance experience
• Compatibility with existing Google apps and services
• Optimized hardware and software components
• Biosensors and companion Android smartphone app designed by Masimo

This partnership is expected to accelerate innovation in the Wear OS ecosystem, offering consumers a wider range of feature-rich devices to choose from.

Masimo (NASDAQ: MASI) issued a statement following two rulings by the U.S. District Court for the Central District of California. The court found Politan Capital Management LP and Quentin Koffey in contempt for violating a court order on September 12, 2024, and determined that Politan made false and misleading statements to stockholders. The court stated that these actions should be considered by stockholders when evaluating proxy votes for the upcoming 2024 Annual Meeting.

The court also found that Politan's false statements improperly influenced recommendations by ISS and Glass Lewis. However, Egan-Jones, after reviewing post-litigation discovery facts, recommended voting for Masimo's director nominees. Masimo urges stockholders to vote 'FOR' Joe Kiani and Christopher Chavez on the updated GOLD proxy card to protect the company's future.

Politan Capital Management, an 8.9% shareholder of Masimo (NASDAQ: MASI), has issued a statement from its legal advisors regarding a proxy contest. The statement, made by representatives from Schulte Roth & Zabel and Munger, Tolles & Olson, expresses disagreement with a court ruling that Politan violated a sealing order. The legal teams believed that while the contents of the order were sealed, the outcome of the motion was not, and had approved Politan's press release on September 12.

Despite disagreeing with the ruling, the legal advisors noted that the court denied Masimo's efforts to prevent Politan from voting and rejected Masimo's attempt to delay the upcoming 2024 Annual Meeting of Stockholders. Politan urges shareholders to vote using the WHITE universal proxy card in support of Politan's nominees and recommendations.

Masimo (NASDAQ: MASI) has issued a statement addressing false claims made by Politan Capital Management LP and Quentin Koffey in their proxy contest. The company's lawsuit has forced Politan to issue corrective disclosures on several misleading statements, including:

1. Lies about the spin-off and the Special Committee's decision
2. False claims about the Board's role in the sale process
3. Misrepresentations about the outcome of the sale process

Masimo urges stockholders to vote 'FOR' its director nominees, Joe Kiani and Christopher Chavez, on the updated GOLD proxy card for the upcoming September 19, 2024 Annual Meeting. The company emphasizes that its recent earnings show its strategy is working and warns against risking this momentum by handing control to an inexperienced team with no clear strategy.

Politan Capital Management, an 8.9% shareholder of Masimo (NASDAQ: MASI), issued a statement regarding a California federal court ruling that denied Masimo's attempt to block Politan from voting proxies it collects. The ruling clears the way for the shareholder vote to proceed on September 19 at Masimo's 2024 Annual Meeting of Stockholders.

Politan expressed satisfaction with the court's decision, stating it removes the last barrier to shareholders electing truly independent directors to Masimo's Board. The company criticized Masimo's litigation as a desperate move to prevent a fair election. Politan also highlighted the need for independent oversight on Masimo's Board, accusing the current Board of recklessly spending shareholder resources and misleading investors.

Masimo (NASDAQ: MASI) urges stockholders to vote 'FOR' Joe Kiani and Christopher Chavez at the September 19, 2024 Annual Meeting. The company emphasizes that this vote will determine Masimo's future leadership and strategy. Key points include:

1. Masimo's current leadership has driven innovation and growth, with 22% healthcare revenue growth year-over-year.

2. The company warns that electing Politan's nominees could lead to a loss of key employees and expertise.

3. Masimo has raised its full-year EPS guidance and aims to double EPS to $8 in five years.

4. The company criticizes Politan's lack of concrete plans and medical technology expertise.

5. Masimo highlights its track record of value creation and commitment to addressing stockholder feedback.

Masimo (NASDAQ: MASI) announced that Saint-Denis Hospital Center in France is adopting the Masimo SafetyNet® cloud-based telemonitoring platform for their experimental mobile neonatology unit. This innovative project, launched in February, aims to facilitate earlier discharge of premature newborns from the ICU to home while maintaining close hospital supervision.

The system uses Masimo's Radius PPG® sensor with SET® technology, worn on the baby's foot, to send health data to a smartphone app for parents and hospital caregivers. This allows for continuous monitoring and quick response to changes in the baby's condition. The project could potentially allow premature babies to return home before the typical 36 weeks of corrected age, benefiting both families and hospital resources.

Masimo (NASDAQ: MASI) is urging stockholders to vote 'FOR' its director nominees, Joe Kiani and Christopher Chavez, at the upcoming Annual Meeting on September 19, 2024. The company has shared details from unredacted legal filings about Quentin Koffey's alleged multi-year plan to take control of Masimo. Key points include:

1. Politan raised nearly $440 million specifically targeting Masimo stock acquisition.
2. Politan allegedly failed to disclose its investors in its 13D filing.
3. Quentin Koffey, as a Masimo director, reportedly hired firms to find former employees willing to provide damaging information about the company.
4. Koffey allegedly threatened other directors and refused to sign required SEC filings.
5. Masimo claims Koffey sabotaged efforts to separate the consumer business.

Masimo argues that Koffey's actions demonstrate he is not acting in the best interests of all stockholders and warns against giving him control of the company.